European Lung Cancer Congress 2019 (ELCC 2019)

Treatment with the ROS1 inhibitor entrectinib yielded deep and durable responses in patients with ROS1 fusion-positive non–small cell lung cancer (ROS1+ NSCLC), including in those with brain metastases, according to a pooled analysis of three studies.

First-line therapy with the anti-programmed death ligand-1 (PD-L1) monoclonal antibody durvalumab improved overall survival (OS) in patients with metastatic non-small-cell lung cancer (NSCLC) compared with platinum-based chemotherapy (CT), according to results from two analyses of the MYSTIC* trial presented at ELCC 2019.

Maintenance immunotherapy with the immune checkpoint inhibitors nivolumab and ipilimumab failed to improve overall survival (OS) in individuals with extensive-stage disease small-cell lung cancer (ED-SCLC), according to CheckMate 451* results presented at ELCC 2019.